Geir O'Rourke

Cancer patients who develop a blood clot while on extended apixaban therapy face a very poor short-term prognosis, with half dying within weeks, a new analysis shows.

High-flow nasal cannula should be first-line therapy for adults with acute hypoxaemic respiratory failure, a new American Thoracic Society guideline recommends. The clinical practice guideline, published in the American Journal of Respiratory and Critical Care Medicine [link here] is the first to comprehensively address noninvasive respiratory support (NIRS) across the full trajectory of acute respiratory failure, from initial presentation through to extubation.

The PBS will subsidise rozanolixizumab (Rystiggo) for generalised myasthenia gravis from July, with around 4,900 Australians expected to benefit each year. The listing gives neurologists a new anti-FcRn option for adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive, according to the TGA-approved Product Information.